ArticlePDF Available

Prolactin and cancer: Has the orphan finally found a home?



Prolactin has, for long, been associated with galactorrhea and infertility in women while its role in men is largely unknown. Recently, expression of prolactin in various other tissues like the breast, prostate, decidua, and the brain has been recognized. This has led to evaluation of paracrine and autocrine actions of prolactin at these tissues and a possible role in development of various cancers. Increased expression of PRL receptors has also been implicated in carcinogenesis. Breast cancer has the strongest association with increased prolactin and prolactin receptor levels. Prostate cancer also has reported significant association, while the role of prolactin in colorectal, gynecological, laryngeal, and hepatocellular cancers is more tenuous. Prolactin/prolactin receptor pathway has also been implicated in development of resistance to chemotherapy. Thus, the effects of this pathway in carcinogenesis seem widespread. At the same time, they also offer an exciting new approach to hormonal manipulation of cancers, especially the treatment-resistant cancers.
Indian Journal of Endocrinology and Metabolism / Vol 16 / Supplement 2 S195
Prolactin and cancer: Has the orphan nally found
a home?
Bipin Kumar Sethi, G.V. Chanukya, V. Sri Nagesh
Department of Endocrinology and Metabolism, Care Hospitals, Banjara Hills, Road Number 1, Hyderabad - 500 034, Andhra, Pradesh, India
Prolactin has, for long, been associated with galactorrhea and infertility in women while its role in men is largely unknown. Recently,
expression of prolactin in various other tissues like the breast, prostate, decidua, and the brain has been recognized. This has led
to evaluation of paracrine and autocrine actions of prolactin at these tissues and a possible role in development of various cancers.
Increased expression of PRL receptors has also been implicated in carcinogenesis. Breast cancer has the strongest association with
increased prolactin and prolactin receptor levels. Prostate cancer also has reported signicant association, while the role of prolactin
in colorectal, gynecological, laryngeal, and hepatocellular cancers is more tenuous. Prolactin/prolactin receptor pathway has also been
implicated in development of resistance to chemotherapy. Thus, the effects of this pathway in carcinogenesis seem widespread. At the
same time, they also offer an exciting new approach to hormonal manipulation of cancers, especially the treatment-resistant cancers.
Key words: Prolactin, cancer, carcinogenesis
Mini Review
Prolactin (PRL), the peptide hormone secreted by the
anterior pituitary gland, has, for long, remained restricted
to the eld of lactation and infertility. While a few studies
recently have dealt with the use of prolactin in differentiating
true and pseudo- seizures, the multiple effects of this
hormone have largely remained unknown. The connection
between prolactin and cancer has been suspected for many
years, but never conclusively proven. The similarity of
prolactin with growth hormone and its actions through the
growth-promoting JAK/STAT pathway suggest its tumor-
promoting effects. Recent research has underlined the role
of PRL and PRL receptor (PRLR) most importantly in
breast and prostate cancers, but also in a variety of other
cancers. This review article has been designed to present
an overview of the recent understanding regarding role of
PRL in cancer and new modalities of cancer therapy based
on the PRL pathway.
Breast cancer
Breast cancer is one of the commonest cancers in women,
with over one million cases reported worldwide, making up
25% of all cancers in women. In spite of the availability
of advanced treatments like surgery, chemotherapy, and
radiotherapy, the disease continues to take its toll, with a
high incidence of treatment failure due to tumor resistance,
both intrinsic and acquired. This has prompted the search
for factors causing it and also the means to counteract
it, and prolactin is one such candidate. The concept of
prolactin as a factor in mammary cancer is not new. It was
initially suggested over three decades ago, based on data
obtained from murine models. For a long time, this animal
data could not be extrapolated to humans due to variety
of reasons: (i) most of these studies involved only a few
subjects, (ii) a concept of local production of prolactin in
breast tissue did not exist, (iii) most of the studies, which
used bromocriptine to reduce serum prolactin levels, did
not lead to successful treatment, and (iv) most of these
Corresponding Author: Bipin Kumar Sethi Department of Endocrinology and Metabolism, Care Hospitals, Banjara Hills, Road Number 1,
Hyderabad - 500 034, Andhra, Pradesh, India. E-mail:
Access this article online
Quick Response Code:
[Downloaded free from on Friday, June 4, 2021, IP:]
Indian Journal of Endocrinology and Metabolism / Vol 16 / Supplement 2
studies did not reach specic conclusions about the relation
between prolactin and breast cancer. However, the high
incidence of treatment failure and a number of recent
epidemiological studies have again shifted the focus back
on to prolactin. These recent studies have brought to fore,
a few critical concepts regarding the role of prolactin
(PRL) in breast cancer. (i) Even high-normal circulating
levels of PRL increase breast cancer risk. (ii) Locally
produced prolactin acts as an autocrine/paracrine factor in
breast cancer evolution. (iii) A causal relationship between
prolactin receptor expression and breast cancer has also
been recognized.[1]
The exact mechanism by which high-normal circulating
levels of PRL leads to increased breast cancer risk is not
exactly known. PRL may promote breast cancer via the
JAK2/STAT5 signaling pathway and may also increase the
survival of breast cancer cells by stimulating generation
of new cancer cells and decreasing cell death. PRL could
also increase cell motility and promote cancer spread. PRL
has also been implicated in causing resistance to cytotoxic
drugs like cisplatin and drugs like paclitaxel, which act on
cellular microtubules.
Circulating prolactin produced by the pituitary is not
the only prolactin available to tissues. Many organs
like the mammary gland, prostate, brain, deciduas, and
skin also express PRL. This extra-pituitary prolactin
probably is involved in development of breast tissue,
dermatological bio-regulation, and perception of pain.
While extra-pituitary secretion has also been reported in
animal models, it is assumed to be much more common
in humans and is dopamine and POU1F1-independent.
A specic regulator of local PRL production has still not
been identied, even though insulin, progesterone, and
transforming growth factor – β have been proposed as
regulators. In the breast, PRL is produced in both the
stromal and epithelial compartments. Further, while very
little prolactin is produced locally, it is very important for
tumor formation due to local availability.
A few studies have also found that breast tumors also
express higher levels of the PRL receptor (PRLR) when
compared to adjacent healthy tissue.[2,3] Even low levels
of prolactin receptor expression are adequate to mediate
actions of PRL in breast cancer cell lines. A family
of prolactin receptor (PRLr) isoforms, numbering six,
mediates the effects of PRL in human tissue. These six
isoforms are variably expressed in normal tissues and
malignant tissues. PRLR-triggered signaling cascades
have also been implicated in benign breast tumors. A
study by Plotnikov et al.[4] found that impaired turnover
of the prolactin receptor in breast cancer cells results in
accelerated proliferation and increased invasive growth.
Conversely, antagonism of the prolactin receptor
resulted in reduction of clonogenic capacity of breast
cancer cells and potentiated the action of cytotoxic anti-
cancer drugs.[5] This has very important implications in
chemotherapy of breast cancer, especially the resistant
types. The local production of prolactin cannot be
controlled by conventional dopamine agonists that act
at the pituitary level. This failure of bromocriptine
(the most commonly used dopamine agonist in cancer
studies) to reduce local PRL levels resulted in the failure
of this drug in cancer studies. This highlights the need
to develop a special category of therapeutic agents
targeted at reducing the action of endogenous PRL by
blocking the PRL receptor. The human PRLR antagonist
G129R-hPRL, which sterically hinders the sequential
dimerization and subsequent activation of the PRLR,
causes apoptosis of both estrogen receptor-positive and
estrogen receptor-negative breast cancer cell lines. In
the study by Howell et al.,[5] the ‘pure’ prolactin receptor
antagonist Δ1–9 signicantly augmented the cytotoxic
effects of doxorubicin and paclitaxel in vitro. This therapy
also inhibited the colony-forming efciency of cell lines
and primary cancers. Autocrine prolactin in breast cancer
cell lines can also be antagonized by prolactin-neutralizing
antibodies.[6] Most of the studies on antibodies have been
in vitro, in which these neutralizing antibodies have been
shown to inhibit MCF-7 and T47Dco cell growth and
to increase cell apoptosis.[7] Thus, these studies suggest
that a judicious combination of cytotoxic agents, PRLR
antagonists/neutralizing antibodies could provide a new
form of therapy for resistant breast cancers. At the
genetic level, construction of a PRLR single nucleotide
polymorphism risk prole for affected patients could
enable personalized treatment strategies.
Interactions between estrogen and prolactin systems
Recent research has indicated significant interaction
between estrogen and prolactin systems. Estrogen
stimulates prolactin secretion and can also up-regulate
human prolactin receptor gene expression and stimulate
growth of tumorigenesis.[8] Prolactin has been shown to
exert some of its effects on mammary tumor cells via the
estrogen receptor. Anti-estrogens like tamoxifen have also
been found to block the prolactin receptors. This could
represent another pathway of cancer therapy, discrete from
the anti-estrogenic effects of these drugs. Interestingly,
hyperprolactinemia results in hypogonadism, suppresses
the ovarian reproductive cycle, and reduces estrogen. Thus,
the interactions between prolactin and estrogen pathways
are complex, and careful studies are needed to formulate
treatment strategies.
Sethi, et al.: Prolactin cancer
[Downloaded free from on Friday, June 4, 2021, IP:]
Indian Journal of Endocrinology and Metabolism / Vol 16 / Supplement 2 S197
pRosTaTe canceR
Prostate cancer is presently the most frequently diagnosed
cancer and represents the second most common cause
of death from cancer in men. PRL has an important
role in the development of prostate gland. In 1955,
Grayhack[9] discovered that when prolactin was inhibited
in rats during embryonic development, only 80% of
the prostate was developed, which shows that prolactin
is important in differentiation and development of
the prostate. There is also signicant evidence of the
existence of prolactin’s paracrine and autocrine actions.
The mainstay of treatment of prostate cancer includes
radical prostatectomy, radiation, and androgen deprivation
therapy. However, just like in breast cancer, resistance
to hormone therapy has also been noted in prostate
cancer. Also, prostate cancer often metastasizes to
the bone, which makes treatment even more difcult.
Epidemiological studies exploring a correlation between
serum PRL levels and prostate cancer incidence or severity
have been equivocal. Both malignant and healthy prostates
produce PRL. The PRL-positive tissues show a good
correlation with activated Stat5 and a high Gleason score.
Prostatic uids from patients with cancer also have higher
PRL levels than controls, which also lend support to the
existence of prostate-derived PRL. Most of the effects of
prolactin on prostate cancer cells are similar to those on
breast cancer cells. In vitro, prolactin induces proliferation
and antagonizes apoptosis in prostate organ culture and in
some tumor cell lines. In humans, receptors for prolactin
are expressed in the prostate, and this expression is
particularly elevated in prostate cancer and carcinoma in
situ. While hypogonadism caused by hyperprolactinemia
could have a role in reduction of prostate cancer, as
reported in a study,[10] the bulk of evidence seems to
suggest that up-regulation of PRLR and local production
of PRL in prostate could be important in increased risk
of prostate cancer and treatment resistance.
coloRecTal canceR
Colorectal cancer is the third highest cause of cancer
mortality worldwide. CEA is the most common marker
utilized for the detection and follow-up of colorectal
cancer. However, a study by Soroush et al.[11] compared
serum PRL and CEA level of 47 patients and found that
serum PRL and CEA levels were increased in patients
with colorectal cancer, but the greater portion of the
patients had an increased level of PRL compared with
elevated level of CEA. They also found no correlation
between the plasma PRL concentration and the stage of
the tumor. They concluded that in view of the high cost
of CEA, prolactin could be used as a tumor marker for
colorectal cancer. Similar results have been found in a study
by Bhatavdekar.[12] However, evidence about the role of
prolactin in colorectal cancer has been mixed, and its role
in colorectal cancer remains contentious.
hepaTocellulaR caRcinoma
Hepatocellular carcinoma (HCC) accounts for more than
6 lakh new cases per year worldwide. Despite several
treatment modalities, the long-term survival rate remains
unsatisfactory, principally due to high rates of recurrence
and metastasis even after treatment. Increased circulating
prolactin levels, high p-JAK2 expression, and generation
of liver cancer cells through PRLR/JAK2 signaling have all
been proposed as mechanisms that could contribute to the
development of HCC. A study by Yeh et al.[13] demonstrated
signicantly higher serum levels of prolactin in people with
HCC, and this signicant relationship existed irrespective
of gender, age, or BMI. These ndings have signicant
implications in the detection and therapy of HCC, if
proven. Hence, larger studies, which can prove the role
of PRL in activation of JAK2 and exclude the role of
other cytokines and growth factors in the JAK2 activation
pathway, need to be designed immediately.
gynecological canceRs
Elevated levels of serum PRL in ovarian and endometrial
cancers have been reported, indicating a potential role for
PRL in gynecological cancers. PRL possibly promotes
tumorigenesis by activating Ras oncogene, and thus
could lead to cells with mutations in tumor suppressor
genes turning malignant. A study by Levina et al.[14] found
dramatically increased expression of PRL receptor in
ovarian and endometrial tumors as well as in endometrial
hyperplasia, signifying the importance of PRL signaling in
malignant and premalignant conditions. PRL mRNA was
expressed in ovarian and endometrial tumors, indicating
the presence of an autocrine loop. Serum PRL levels were
also signicantly elevated in women with a strong family
history of ovarian cancer, and this PRL rise could not be
attributed to stress.
malignanT laRyngeal TumoRs
Laryngeal cancer (LC) is responsible for approximately
159,000 new cases and 90,000 mortalities every year. The
mechanisms underlying the proliferation of this form of
cancer are not yet fully understood. A recent study by
González-Lucano et al.[15] found increased expression of
different isoforms of PRLR in LC in comparison with
recurrent respiratory papillomatosis. This suggested a
Sethi, et al.: Prolactin cancer
[Downloaded free from on Friday, June 4, 2021, IP:]
Indian Journal of Endocrinology and Metabolism / Vol 16 / Supplement 2
possible role of PRL/PRLR in the development of LC.
They concluded that PRLR might be useful as a target for
further investigations in laryngeal tissues.
all cause moRTaliTy
In view of the widespread expression of PRL in various
tissues and the emerging role of prolactin in causing
multiple cancers, a study was devised by Berinder et al.[10]
to assess the overall relative risk of cancer and risk of
some specic a priori specied cancer forms in a cohort
of 969 women and men with hyperprolactinemia. Their
results were different from the majority of prolactin and
cancer studies, and they reported a higher incidence of
upper gastrointestinal cancer in both males and females
and hematopoietic cancer in females. Risk of breast cancer
was not increased in women, and there was a reduced risk
of prostate cancer in men. An increased overall cancer risk
was found in hyperprolactinemia patients.
The last word on the role of PRL in causing cancer and
on its receptor conferring resistance to chemotherapeutic
agents is yet to be written. The more the number of cancers
added to the list, the more is the story getting curiouser and
curiouser. Clearly, an association has been demonstrated,
but whether that is a cause and effect relationship is yet
to be established. The modest PRL elevations could
be of local origin. Higher levels that are obtained in
prolactinomas usually cause hypogonadism, something that
chemotherapies for breast and prostate cancer treatment
aim at, and hence this high serum PRL certainly cannot be
blamed for causing these cancers.
1. Bernichtein S, Touraine P, Goffin V. New concepts in prolactin
biology. J Endocrinol 2010;206:1-11.
2. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV.
Expression of prolactin and its receptor in human breast carcinoma.
Endocrinology 1997;138:5555-60.
3. Tran-Thanh D, Arneson NC, Pintilie M, Deliallisi A, Warren KS, Bane
A, et al. Amplification of the prolactin receptor gene in mammary
lobular neoplasia. Breast Cancer Res Treat 2011;128:31-40.
4. Plotnikov A. Impaired turnover of prolactin receptor contributes to
transformation of human breast cells. Cancer Res 2009;69:3165-72.
5. Howell SJ, Anderson E, Hunter T, Farnie G, Clarke RB. Prolactin
receptor antagonism reduces the clonogenic capacity of breast cancer
cells and potentiates doxorubicin and paclitaxel cytotoxicity. Breast
Cancer Res 2008;10:R68.
6. Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE. A
human prolactin antagonist, hPRL-G129R, inhibits breast cancer
cell proliferation through induction of apoptosis. Clin Cancer Res
7. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly
JM. Prolactin acts as a potent survival factor for human breast cancer
cell lines. Br J Cancer 2004;91:305-11.
8. Dong J, Tsai-Morris CH, Dufau ML. A novel estradiol/estrogen
receptor a-dependent transcriptional mechanism controls expression
of the human prolactin receptor. J Biol Chem 2006;281:18825-36.
9. Grayhack J, Bunce P, Kearns J, Scott W. Influence of the pituitary
on prostatic response to androgen in the rat. Bull Johns Hopkins
Hosp 1955;96:154-63.
10. Berinder K, Akre O, Granath F, Hulting AL. Cancer risk in
hyperprolactinemia patients: A population-based cohort study. Eur
J Endocrinol 2011;165:209-15.
11. Soroush AR, Zadeh HM, Moemeni M, Shakiba B, Elmi S. Plasma
prolactin in patients with colorectal cancer. BMC Cancer 2004;4:97.
12. Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH,
Ghosh N, et al. Ectopic production of prolactin by colorectal
adenocarcinoma. Dis Colon Rectum 2001;44:119-27.
13. Yeh YT, Lee KT, Tsai CJ, Chen YJ, Wang SN. Prolactin Promotes
Hepatocellular Carcinoma through Janus Kinase 2. World J Surg
14. Levina VV, Nolen B, Su Y, Godwin AK, Fishman D, Liu J, et al.
Biological significance of prolactin in gynecologic cancers. Cancer
Res 2009;69:5226-33.
15. González-Lucano LR, Muñoz-Valle JF, Ascencio-Cedillo R,
Domínguez-Rosales JA, López-Rincón G, Del Toro-Arreola S, et
al. Increased expression of the prolactin receptor is associated with
malignant laryngeal tumors. Exp Ther Med 2012;3:603-7.
Cite this article as: Sethi BK, Chanukya GV, Nagesh VS. Prolactin and cancer:
Has the orphan nally found a home?. Indian J Endocr Metab 2012;16:S195-8.
Source of Support: Nil, Conict of Interest: None declared.
Sethi, et al.: Prolactin cancer
[Downloaded free from on Friday, June 4, 2021, IP:]
... These hormones might directly influence the expression of genes, interact with signal transduction routes of steroid hormones, and probably mediate some properties of steroid actions [22]. The peptide hormone prolactin (PRL) is secreted mainly by the pituitary gland and, to a lesser extent, by peripheral tissues, such as the breast, decidua, prostate, and the brain, and it is involved in a broad spectrum of physiological processes in vertebrates [23]. The principal stimulatory and inhibitory control of prolactin secretion is a hypothalamic hormone that inhibits the prolactin secretion the dopamine. ...
... Clinical and experimental studies have demonstrated the pleiotropic role of prolactin, stimulating cellular proliferation and secretory activity in the prostate, under normal or pathological conditions [27]. PRL has been associated with a number of different forms of cancer, among them human breast and prostate cancer [23,25]. Besides, hyperprolactinemy is associated with amenorrhea, galactorrhea, pseudo-pregnancy and infertility in women [28]. ...
... Besides, hyperprolactinemy is associated with amenorrhea, galactorrhea, pseudo-pregnancy and infertility in women [28]. Human patients with benign prostatic hyperplasia or prostate cancer have higher blood levels of PRL [23]. Hyperprolactinemia caused enlargement and inflammation of the lateral rat prostate [29]. ...
Full-text available
Background: The male and female prostates are controlled by steroid hormones, suffering important morphological and physiological changes after castration. Prolactin is involved in the regulation of the male prostate, having already been identified in the tissue, acting through its receptor PRLR. In the Mongolian gerbil, in addition to the male prostate, the female prostate is also well developed and active in its secretion processes. The aim of the present study was to evaluate the effects of exposure to exogenous prolactin in the prostate of both intact and castrated male and female gerbils in order to establish if prolactin administration can sustain prostate cell activity in conditions of sexual hormone deprivation. Methods: The morphological analyses were performed by biometric analysis, lesion histological analysis and morphometric-stereological aspects. In addition, immune-cytochemical tests were performed for prolactin and its receptor, as well as for the receptors of androgen and oestrogen and serum prolactin dosage. All data were submitted to ANOVA or Kruskal-Wallis tests for comparison between groups. P < 0.05 was considered to be statistically significant. Results: The results showed a strong influence of prolactin on the morphology of the prostate, with the development of important epithelial alterations, after only 3 days of administration, and an expressive epithelial cell discard process after 30 days of administration. Prolactin acts in synergy with testosterone in males and mainly with oestrogens in females, establishing different steroid hormonal receptor immunoreactivity according to sex. It was also demonstrated that prolactin can assist in the recovery from some atrophic effects caused in the gland after castration, without causing additional tissue damage. Conclusions: The prolactin and its receptor are involved in the maintenance of the homeostasis of male and female gerbils, and also cause distinct histological alterations after exogenous exposure for 3 and 30 days. The effects of prolactin are related to its joint action on androgens and oestrogens and it can also assist in the recovery from the atrophic effects of castration.
... Whether the secretions of the uterine glands directly stimulate trophoblast invasion remains elusive. Increased prolactin levels have also been linked to the higher invasiveness of specific tumor types [234,236]. This correlation seems to be particularly strong in breast cancer. ...
... This correlation seems to be particularly strong in breast cancer. The similarity between prolactin and growth hormones and its influence on the JAK/STAT signaling pathway strongly indicate its impact on tumor invasiveness [236]. Hence, it is assumed that both trophoblast and tumor invasion are also affected and regulated by the hormonal products produced by cells of their microenvironments [215,236]. ...
... The similarity between prolactin and growth hormones and its influence on the JAK/STAT signaling pathway strongly indicate its impact on tumor invasiveness [236]. Hence, it is assumed that both trophoblast and tumor invasion are also affected and regulated by the hormonal products produced by cells of their microenvironments [215,236]. ...
Full-text available
Placenta-specific trophoblast and tumor cells exhibit many common characteristics. Trophoblast cells invade maternal tissues while being tolerated by the maternal immune system. Similarly, tumor cells can invade surrounding tissues and escape the immune system. Importantly, both trophoblast and tumor cells are supported by an abetting microenvironment, which influences invasion, angiogenesis, and immune tolerance/evasion, among others. However, in contrast to tumor cells, the metabolic, proliferative, migrative, and invasive states of trophoblast cells are under tight regulatory control. In this review, we provide an overview of similarities and dissimilarities in regulatory processes that drive trophoblast and tumor cell fate, particularly focusing on the role of the abetting microenvironments.
... Prolactin has an important role in lactation but has since expanded to encompass an array of functions, ranging from metabolic homeostasis to maternal behaviour [47]. In gynaecological cancers, prolactin is implicated in ovarian and endometrial cancer, where PRLR is found to be upregulated [134]. Linher-Melville et al., found prolactin stimulated the expression and activity of CPTIA in MDA-MB-231 cells, in an AMPK-dependent manner. ...
Full-text available
Gynaecological cancers are among the leading causes of cancer-related death among women worldwide. Cancer cells undergo metabolic reprogramming to sustain the production of energy and macromolecules required for cell growth, division and survival. Emerging evidence has provided significant insights into the integral role of fatty acids on tumourigenesis, but the metabolic role of high endogenous oestrogen levels and increased gynaecological cancer risks, notably in obesity, is less understood. This is becoming a renewed research interest, given the recently established association between obesity and incidence of many gynaecological cancers, including breast, ovarian, cervical and endometrial cancers. This review article, hence, comprehensively discusses how FA metabolism is altered in these gynaecological cancers, highlighting the emerging role of oestradiol on the actions of key regulatory enzymes of lipid metabolism, either directly through its classical ER pathways, or indirectly via the IGIFR pathway. Given the dramatic rise in obesity and parallel increase in the prevalence of gynaecological cancers among premenopausal women, further clarifications of the complex mechanisms underpinning gynaecological cancers are needed to inform future prevention efforts. Hence, in our review, we also highlight opportunities where metabolic dependencies can be exploited as viable therapeutic targets for these hormone-responsive cancers.
... In this case, dopaminergic agonists may play an important pharmacological role by lowering prolactin levels and reducing liver metastases [68]. Long-term hyperprolactinemia may be a risk factor for the onset of breast or prostate cancer [69], and for an unfavorable evolution of oncological disease [70]. The involvement of dopamine in cancer remains intensely debated, which on the one hand can promote the development of cancer and on the other hand can induce apoptosis of cancer cells, depending on the mechanisms involved in oncogenesis [71,72]. ...
Full-text available
Introduction: Atypical antipsychotics have numerous benefits compared to conventional ones in respect to the possible adverse effects. However, like the other ones, they may induce direct cardiovascular alterations, probably through the apoptotic effect of dopamine receptor D2 (DRD2) blockade. The main objective of the study was to assess the cardiac ejection fraction (EF) using transthoracic speckle tracking echocardiography (TSTE) in patients treated with long-acting injectable (LAI) atypical antipsychotics. Patients, materials and methods: This cross-sectional study was conducted on 123 patients with schizophrenia or schizoaffective disorder divided in four samples according to their treatment: Aripiprazole, Olanzapine, Paliperidone and Risperidone. We analyzed socio-demographic data, the intensity of psychiatric symptoms, the duration of psychosis and of LAI treatment, and the cardiac EF measured with TSTE. Results: We found no statistically significant differences between the four antipsychotics regarding the values of the EF. Nevertheless, we observed a trend indicating that patients treated with an antipsychotic associated with a lower affinity for the DRD2, such as Olanzapine, have higher EF values than patients treated with antipsychotics with a stronger binding to the DRD2, such as Paliperidone and Risperidone. Patients receiving Aripiprazole, which has the strongest affinity for the DRD2 from all four antipsychotics but is also a partial DRD2 agonist, display higher EF values than those on Paliperidone and Risperidone. Conclusions: Antipsychotics with a lower affinity for the DRD2 or a partial agonism for it may be associated with higher EF. Cardiac monitoring should be performed periodically in patients on LAI antipsychotic therapy.
... Hyperprolactinemia was almost always detected in individuals with metastatic breast cancer during the course of the disease, and it was a significant indicator of poor prognosis in node-positive breast cancer patients (17). Prolactin may boost the survival of breast cancer cells by inducing the production of new cancer cells and inhibiting cell death via the Janus-activated kinase-2/signal transducers and activators of transcription-5 (JAK2/STAT5) signaling pathway (18). Prolactin-estrogen crosstalk is bidirectional and can happen at var ious levels. ...
Full-text available
Background and objectives: Prolactin is a lactogenic protein hormone secreted by the anterior pituitary that initiates and maintains lactation in mammals. Previous research has linked increased serum prolactin levels to breast cancer. However, there is a paucity of studies in the Indian population on the subject. The present study evaluated and compared serum prolactin levels in patients with breast cancer and patients with benign breast diseases. Methods: This cross-sectional, comparative study was carried out at the Government Medical College, Nagpur (India) on patients with breast diseases in the out-patient department/in-patient department from June 2018 to November 2020. Breast cancer patients were considered cases, and those with benign breast diseases were considered controls. Breast carcinoma diagnosis was based on clinical features, fine needle aspiration cytology, and tissue histopathology in operated specimens for each patient. Fasting serum prolactin levels were measured by the chemiluminescence immunoassay method using the Advia Centaur immunoassay system. Results: There were 120 female patients with breast diseases, of whom 60 had breast malignancy, and 60 had benign breast diseases. The mean age of patients with benign breast disease and breast cancer was 33.17 (1.75) and 49.77 (1.16) years, respectively (P40.2 ng/ml) to differentiate breast cancer from benign breast diseases using the receiver operating characteristic curve analysis. Conclusion: Patients with breast cancer have increased serum prolactin levels compared to patients with benign breast diseases. Thus, serum prolactin level can be used as a diagnostic marker for breast cancer. This is particularly beneficial to clinicians for differentiating breast cancer from benign breast diseases.
... PRL promotes the initiation and progress of different gynecological neoplasms through different mechanisms. Furthermore, it is known that they share the cellular effects exerted through the JAK/STAT signaling cascade, such as survival, cell cycle progression, proliferation, migration, high metabolic rates, angiogenesis, and anti-apoptosis (9,12,(29)(30)(31)(32)(33)(34)(35)(36). In addition to this, it has been found that the PRLR is overexpressed in breast (14,37), cervical (38)(39)(40), ovarian (41,42), and endometrial cancer (EC) (2,43) in comparison with their respective cancer-free tissues. ...
Full-text available
Prolactin (PRL) is a hormone produced by the pituitary gland and multiple non-pituitary sites, vital in several physiological processes such as lactation, pregnancy, cell growth, and differentiation. However, PRL is nowadays known to have a strong implication in oncogenic processes, making it essential to delve into the mechanisms governing these actions. PRL and its receptor (PRLR) activate a series of effects such as survival, cellular proliferation, migration, invasion, metastasis, and resistance to treatment, being highly relevant in developing certain types of cancer. Because women produce high levels of PRL, its influence in gynecological cancers is herein reviewed. It is interesting that, other than the 23 kDa PRL, whose mechanism of action is endocrine, other variants of PRL have been observed to be produced by tumoral tissue, acting in a paracrine/autocrine manner. Because many components, including PRL, surround the microenvironment, it is interesting to understand the hormone's modulation in cancer cells. This work aims to review the most important findings regarding the PRL/PRLR axis in cervical, ovarian, and endometrial cancers and its molecular mechanisms to support carcinogenesis.
... In the estrogen signaling pathway, estrogen exposure to chronic inflammatory disease activity is a key risk in breast cancer progression [76]. With regards to the prolactin signaling pathway, prolactin functions as a cytokine immune system, especially in breast cancer, which has the strongest correlation with an increased expression level of prolactin and prolactin receptors [77,78]. In the thyroid signaling pathway, the optimal regulation of the cellular thyroid hormone is essential for an adequate role of immune cells during inflammation [79]. ...
Full-text available
Cirsium japonicum var. maackii (Maxim.) Matsum. or Korean thistle flower is a herbal plant used to treat tumors in Korean folk remedies, but its essential bioactives and pharmacological mechanisms against cancer have remained unexplored. This study identified the main compounds(s) and mechanism(s) of the C. maackii flower against cancer via network pharmacology. The bioactive from the C. maackii flower were revealed by gas chromatography-mass spectrum (GC-MS), and SwissADME evaluated their physicochemical properties. Next, target(s) associated with the obtained bioactives or cancer-related targets were retrieved by public databases, and the Venn diagram selected the overlapping targets. The networks between overlapping targets and bioactives were visualized, constructed, and analyzed by RPackage. Finally, we implemented a molecular docking test (MDT) to explore key target(s) and compound(s) on AutoDockVina and LigPlot+. GC-MS detected a total of 34 bioactives and all were accepted by Lipinski’s rules and therefore classified as drug-like compounds (DLCs). A total of 597 bioactive-related targets and 4245 cancer-related targets were identified from public databases. The final 51 overlapping targets were selected between the bioactive targets network and cancer-related targets. With Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment, a total of 20 signaling pathways were manifested, and a hub signaling pathway (PI3K-Akt signaling pathway), a key target (Akt1), and a key compound (Urs-12-en-24-oic acid, 3-oxo, methyl ester) were selected among the 20 signaling pathways via MDT. Overall, Urs-12-en-24-oic acid, 3-oxo, methyl ester from the C. maackii flower has potent anti-cancer efficacy by inactivating Akt1 on the PI3K-Akt signaling pathway
Full-text available
Haloperidol is a routine drug for schizophrenia and palliative care of cancer; it also has antitumor effects in several types of cancer. However, the role of haloperidol in endometrial cancer (EC) development is still unclear. Here, we show that chronic haloperidol treatment in clinically relevant doses induced endometrial hyperplasia in normal mice and promoted tumor growth and malignancy in mice with orthotopic EC. The pharmacokinetic study indicated that haloperidol highly accumulated in the uterus of mice. In vitro studies revealed that haloperidol stimulated the cellular transformation of human endometrial epithelial cells (HECCs) and promoted the proliferation, migration, and invasion of human endometrial carcinoma cells (HECCs) by activating nuclear factor kappa B (NF-κB) and its downstream signaling target, colony-stimulating factor 1 (CSF-1). Gain of function of CSF-1 promotes the cellular transformation of HEECs and the malignant progression of HECCs. Moreover, blockade of CSF-1 inhibited haloperidol-promoted EC progression in vitro and in vivo. A population-based cohort study of EC patients further demonstrated that the use of haloperidol was associated with increased EC-specific mortality. Collectively, these findings indicate that clinical use of haloperidol could potentially be harmful to female patients with EC.
The physiology of breast right from its development in utero to different stages of a woman’s life involves a complex interplay of different hormones and growth factors acting through endocrine, paracrine and autocrine mechanisms. Estrogen promotes ductal development. Progesterone is responsible for lobuloalveolar differentiation. Prolactin mediates lactation which is the primary physiologic role of breast. Other hormones like Growth hormone, Insulin and Thyroid hormones play a permissive role. In addition growth factors mainly Insulin like growth factor 1 (IGF 1), Epidermal growth factor (EGF), Amphiregulin, Neuregulin, wnt and RANKL also play major roles as mediators of growth and differentiation in concert with estrogen and progesterone. Estrogen plays a major role in breast carcinogenesis by its mitogenic effects through genomic and non genomic actions. This explains why it is the key target in hormonal manipulation therapy for breast cancer. EGF has mitogenic effects through its receptor HER2. Crosstalk between Estrogen, IGF 1 and EGF actions plays a significant role in pathogenesis. This is the basis for current and future targeted pharmacotherapies. The cycles of differentiation during pregnancy and lactation followed by the process of post lactation involution have important implications in protecting against neoplastic transformation.KeywordsEstrogenProgesteroneProlactinEpidermal growth factorHER 2Mammary ductsLobuloalveolar differentiationLactationInvolutionBreast carcinogenesis
Prolactin (PRL) is a key hormone involved in canine mammary development and tumorigenesis. In this study, the influence of a single nucleotide polymorphism (SNP) in the PRL gene (rs23932236) on the clinicopathological parameters and survival of dogs with canine mammary tumors (CMTs) was investigated. A total of 206 female dogs with spontaneous mammary tumors were enrolled in this study and circulating blood cells were genotyped. This specific SNP was associated with larger size (>3 cm diameter) for malignant tumors ( P = .036), tumors with infiltrative/invasive growth pattern ( P = .010), vascular invasion ( P = .006), and lymph node metastasis ( P = .004). Carriers of the variant allele had a shorter overall survival compared to the wild-type population with an overall survival of 18.7 months and 22.7 months, respectively ( P = .004). These findings suggest that SNP rs23932236 of canine PRL gene may be used as an indicator for the development of clinically aggressive forms of CMTs.
Full-text available
Hepatocellular carcinoma (HCC) is one human cancer with obvious gender disparity. This study investigated the association of aberrant prolactin levels with HCC risk and the potential impacts on HCC of the prolactin receptor (PRLR)/Janus kinase 2 (JAK2) signaling. Serum prolactin of 63 HCC patients and 162 subjects without HCC was measured by radioimmunoassay. The expressions of PRLR and phosphorylated JAK2 (p-JAK2) in 82 retrospectively collected HCC specimens were evaluated by immunohistochemistry and further incorporated into the survival analysis. The immunoblotting and proliferation assays were used to analyze the effects of PRLR/JAK2 signaling on liver cancer cells with prolactin treatment. Serum prolactin level was significantly higher in HCC patients than in controls. Hepatocellular carcinoma patients with high p-JAK2 expression had a significantly higher postoperative risk than those with low p-JAK2 expression. Moreover, results from the multivariate analysis indicated the prognostic role of p-JAK2 expression with respect to overall survival in HCC patients. In addition, the Kaplan-Meier survival curve showed that high p-JAK2 expression was associated with poor survival in HCC patients with high PRLR expression. The immunoblotting assay showed that prolactin induced the expression of both p-JAK2 and cyclin D1 in Hep-G2 cells. Importantly, the proliferative effects induced by prolactin could be effectively attenuated by adding AG490, a JAK2 inhibitor. Increased circulating prolactin was found in HCC patients and high p-JAK2 expression could predict poor overall survival in those patients expressing high PRLR. In addition, prolactin contributed to the proliferation of liver cancer cells through PRLR/JAK2 signaling.
Full-text available
Human prolactin (PRL) is currently viewed as a hormone of pituitary origin, whose production (i.e. serum levels) is controlled by dopamine, whose biological actions relate exclusively to lactation and reproductive functions, for which any genetic disorder is yet to be identified, and whose unique associated pathology is hyperprolactinemia. Both experimental studies and human sample/cohort-based investigations performed during the past decade have considerably widened our perception of PRL biology: i) there are now strong epidemiological arguments supporting the fact that circulating PRL is a risk factor for breast cancer, ii) in addition to the endocrine hormone, locally produced PRL has been documented in several human tissues; there is increasing evidence supporting the tumor growth potency of local PRL, acting via autocrine/paracrine mechanisms, in both rodent models, and human breast and prostate tumors, iii) the first functional germinal polymorphisms of the PRL receptor were recently identified in patients presenting with breast tumors, which involve single amino acid substitution variants exhibiting constitutive activity, iv) human PRL analogs have been engineered, which were shown in experimental models to down-regulate the effects triggered by local PRL (competitive antagonism) or by the constitutively active receptor variants (inverse agonism). The aim of this review is to discuss these novel concepts in PRL biology, including their potential pathophysiological outcomes.
Full-text available
There is increasing evidence that prolactin (PRL), a hormone/cytokine, plays a role in breast, prostate, and colorectal cancers via local production or accumulation. Elevated levels of serum PRL in ovarian and endometrial cancers have been reported, indicating a potential role for PRL in endometrial and ovarian carcinogenesis. In this study, we show that serum PRL levels are significantly elevated in women with a strong family history of ovarian cancer. We show dramatically increased expression of PRL receptor in ovarian and endometrial tumors as well as in endometrial hyperplasia, signifying the importance of PRL signaling in malignant and premalignant conditions. PRL mRNA was expressed in ovarian and endometrial tumors, indicating the presence of an autocrine loop. PRL potently induced proliferation in several ovarian and endometrial cancer cell lines. Binding of PRL to its receptor was followed by rapid phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, mitogen-activated protein kinase/ERK kinase 1, signal transducer and activator of transcription 3, CREB, ATF-2, and p53 and activation of 37 transcription factors in ovarian and endometrial carcinoma cells. PRL also activated Ras oncogene in these cells. When human immortalized normal ovarian epithelial cells were chronically exposed to PRL, a malignant transformation occurred manifested by the acquired ability of transformed cells to form clones, grow in soft agar, and form tumors in severe combined immunodeficient-beige mice. Transformation efficiency was diminished by a Ras inhibitor, providing proof that PRL-induced transformation uses the Ras pathway. In summary, we present findings that indicate an important role for PRL in ovarian and endometrial tumorigenesis. PRL may represent a risk factor for ovarian and endometrial cancers.
Full-text available
Signaling by polypeptide hormone prolactin (PRL) is mediated by its cognate receptor (PRLr). PRLr is commonly stabilized in human breast cancer due to decreased phosphorylation of residue Ser349, which when phosphorylated recruits the betaTrcp E3 ubiquitin ligase and facilitates PRLr degradation. Here, we show that an impaired PRLr turnover results in an augmented PRL signaling and PRL-induced transcription. Human mammary epithelial cells harboring degradation-resistant PRLr display accelerated proliferation and increased invasive growth. Conversely, a decrease in PRLr levels achieved by either pharmacologic or genetic means in human breast cancer cells dramatically reduced transformation and tumorigenic properties of these cells. Consequences of alteration of PRLr turnover for homeostasis of mammary cells and development of breast cancers, as well as the utility of therapies that target PRLr function in these malignancies, are discussed.
The altered expression of the prolactin receptor (PRLR) has been associated with the development of various types of cancer, particularly breast, prostate and endometrial cancer. However, in laryngeal tumors, the expression of PRLR has not yet been documented. The aim of this study was to determine the expression and localization of PRLR in laryngeal cancer (LC) in comparison with recurrent respiratory papillomatosis (RRP). PRLR expression was analyzed in 48 paraffin-embedded tissues (18 RRP and 30 laryngeal cancer tissues) by immunoperoxidase staining. Furthermore, PRLR expression was evaluated in ten samples from each group by Western blot analysis and quantitative real-time PCR. PRLR was observed in all laryngeal tumors at different intensities. PRLR overexpression was significantly associated (P<0.005) with LC. The staining pattern was homogeneous, mainly cytoplasmic, and confined to the tumor area. We found increased expression of different isoforms in LC in comparison with RRP. Our results suggest a possible role of PRL/PRLR in the development of LC. PRLR may be useful as a target for further investigations in laryngeal tissues.
Experimental evidence indicates that prolactin might play a role in tumorigenesis of several human cancers, but data on cancer risk in hyperprolactinemia patients are sparse. The aim of this study was to investigate cancer risk in hyperprolactinemia patients. Design A population-based matched cohort study in Sweden. The hyperprolactinemia cohort consisted of patients hospitalized for hyperprolactinemia from 1987 to 1995 identified in the National Patient Register (n=585) and a hospital cohort of prolactinoma patients at Karolinska University Hospital (n=384). For each patient, ten matched individuals were identified via the Register of Population. Cancer occurrence was ascertained via the Swedish Cancer Registry. Hazard ratios (HRs) were estimated by Cox proportional hazards regression. Seventy-three malignant tumors were identified in the hyperprolactinemia patients and 660 tumors in the comparison group (HR 1.31; 95% confidence interval (CI): 1.02-1.68), mainly attributed to an increased risk of upper gastrointestinal cancer in both males and females (HR 3.69; 95% CI: 1.70-8.03) and hematopoietic cancer in females (HR 3.51; 95% CI: 1.06-11.6). Twelve breast cancers occurred in the female patients, corresponding to an HR of 1.09 (95% CI: 0.60-1.99). Prostate cancer risk in hyperprolactinemia men was reduced (HR 0.40; 95% CI: 0.16-0.99). An increased overall cancer risk was found in hyperprolactinemia patients, but no increased risk of breast cancer in women and a reduced risk of prostate cancer in men. These findings warrant further investigations and to be confirmed in larger studies but may indicate the importance of an active treatment strategy and follow-up of hyperprolactinemia patients.
The identification of lobular carcinoma in situ (LCIS) in a patient's specimen confers an appreciable increased risk of development of future invasive mammary carcinoma. However, the study of LCIS presents a challenge as it is usually only recognized in fixed specimens. Recent advances in high throughput genomics have made possible comprehensive copy number analysis of lesions such as this. Using array comparative genomic hybridization (aCGH), we characterized eight cases of lobular carcinoma (four invasive and four non-invasive) from microdissected samples of archival specimens and validated our results by quantitative real-time PCR (qRT-PCR). Immunohistochemistry (IHC) was performed on an independent set of 80 in situ ductal (DCIS) and lobular breast lesions to confirm our results. Amplification of the prolactin receptor gene (PRLr) was identified in 4/4 cases of LCIS by aCGH. We confirmed this amplification by qRT-PCR and demonstrated PRLr expression in 29/40 (73%) cases of lobular neoplasia by IHC. Amplification of PRLr was neither detected in 10 cases of DCIS nor in 5 areas of normal breast tissue by qRT-PCR and only 14/40 (35%) cases of DCIS showed PRLr expression by IHC (P = 0.0008). Our study suggests the prolactin receptor gene is a molecular target that may be important in the pathogenesis and progression of lobular neoplasia. Investigation of the status of this gene in cases of DCIS has indicated that it may not be as important in the progression of this type of breast cancer, supporting the view that lobular and ductal carcinomas may evolve along separate pathways.
Adipokines play an important role in metabolic regulations. Obesity, diabetes, and renal disturbances affect adipokine profile by influencing their complex effects on metabolism. Our objective was to assess the effect of low-energy diet intervention on serum adiponectin, leptin, and resistin levels in diabetic nephropathy. Seventeen subjects with diabetes type 2 and nephropathy participated in the study. After estimation of individual resting metabolic rates by indirect calorimetry, diets introducing 20% energy deficit were applied. At baseline and after 2 months of dieting, the following parameters were measured: body composition by dual x-ray spectrometry and serum adiponectin (Adp), leptin (Lep), resistin (Res), insulin, urea, creatinine, glucose, glycosylated hemoglobin, C-reactive protein, and tumor necrosis factor-alpha concentrations. Homeostatic model assessment (HOMA) was used to quantify insulin resistance. Total energy, protein, and fat intakes diminished significantly with intentional dieting. Significant decreases in total body fat mass (FM) and its percentage in body mass (FM%) and trunk and gynoid fat mass, as well as in serum resistin and tumor necrosis factor-alpha levels, were also observed. Responses of adipokines to dietary treatment varied individually. Generally, they were affected by FM. Alterations in Lep concentrations correlated negatively with baseline FM, FM%, and android and gynoid fat mass and positively with changes in intake of protein, carbohydrates, and total energy of the consumed diet. Changes in Adp were inversely related to FM after therapy. Alterations in Res concentrations correlated positively with android fat mass before therapy and initial Lep levels. Adiponectin was inversely related to HOMA index before and after treatment. Low-energy diet applied in diabetic nephropathy may decrease serum resistin levels and inflammation. In addition, responses of all adipokines to dieting appear to be affected by body fat mass, especially android fat mass.
Bone growth occurs in the growth-plate cartilage located at the ends of long bones. Changes in the architecture, abnormalities in matrix organization, reduction in protein staining and RNA expression of factors involved in cell signaling have been described in the growth-plate cartilage of nephrectomized animals. These changes can lead to a smaller growth plate associated with decrease in chondrocyte proliferation, delayed hypertrophy, and prolonged initiation of mineralization and vascular invasion. As a result, chronic renal failure can result in stunted body growth and skeletal deformities. Multiple etiologic factors can contribute to impaired bone growth in renal failure, including suboptimal nutrition, metabolic acidosis, and secondary hyperparathyroidism. Recent findings have also shown the tight connection between chondro/osteogenesis, hematopoiesis, and immunogenesis.
End-stage renal disease (ESRD) is commonly associated with anorexia, malnutrition and inflammation. In addition to serving as the primary reservoir for energy storage, adipocytes produce numerous pro- and anti-inflammatory mediators and regulate food intake by releasing the appetite-suppressing (leptin) and appetite-stimulating (adiponectin) hormones. Under normal conditions, release of leptin is stimulated by feeding to prevent excess intake, and release of adiponectin is stimulated by fasting to induce feeding. However, under certain pathological conditions such as inflammation, maladaptive release of these hormones leads to anorexia, wasting and malnutrition and simultaneously intensifies inflammation. Anorexia, malnutrition and inflammation in ESRD are frequently accompanied by hyper-leptinaemia. This study was designed to test the hypothesis that uraemic plasma may stimulate leptin release and suppress adiponectin release in normal adipocytes. Visceral adipose tissue was harvested from normal rats, and adipocytes were isolated and incubated for 2-4 h in media containing 90% plasma from 12 ESRD patients (before and after haemodialysis) and 12 normal control subjects. The ESRD group had a marked elevation of plasma TNF-alpha, IL-6, IL-8 and leptin concentrations before and after haemodialysis. Incubation in media containing plasma from the ESRD group elicited a much greater leptin release by adipocytes than that containing normal plasma. Post-dialysis plasma evoked an equally intense leptin release. The rise in leptin release was coupled with a parallel fall in TNF-alpha concentration in the incubation media. In contrast to leptin, adiponectin release in the presence of uraemic plasma was similar to that found with the control plasma. Exposure to uraemic plasma induces exuberant release of leptin that is coupled with avid uptake of TNF-alpha by visceral adipocytes. These observations confirm the role of TNF-alpha, formerly known as cachexin, in the over-production and release of leptin in patients with ESRD.